Question explored with the scientific record
Vaccines in infants. Simple pros and cons, risks of taking and risks of not taking
The short version: some infant vaccines have real hard-outcome data behind them; most of the safety half of the ledger was never properly measured, and no study here compared vaccinated infants to a genuinely untreated group over years.
For a parent, the honest calculus depends on the disease. Measles is not a mild childhood rite: Romania's 2016-2019 outbreak produced 17,533 cases and 64 deaths, and 45 of the 64 deaths were infants a year old or younger [7]. Rotavirus vaccination cut rotavirus hospitalizations by a median 59% across 49 countries [2]. Infant pneumococcal vaccination was linked to a 47% drop in non-bacteremic pneumococcal pneumonia hospitalizations in infants under two [3]. Clesrovimab (an antibody shot, not a vaccine) reduced RSV hospitalization by about 91% in a randomized placebo-controlled trial [4]. That is real evidence, mostly observational, with real clinical endpoints.
The other side is thinner and messier. A Danish cohort of over a million children found three DTP doses versus none gave an adjusted hazard ratio of 1.51, confidence interval 0.96 to 2.38, not significant [5]. A WHO review of 17 observational studies found an average relative risk of 1.38 (0.92-2.08), all high risk of bias [5]. A VAERS analysis flagged seizure associations with DTP and neurological signals with MMR and hepatitis B in infants up to three years [6]. VAERS is voluntary reporting, so it detects almost nothing by design and cannot prove causation, but it also cannot exonerate.
| Comparison | Number | Source |
|---|---|---|
| Rotavirus, hospitalization drop | 59% median | [2] |
| PCV, pneumonia hospitalization drop (under 2) | 47% | [3] |
| RSV antibody, hospitalization drop | 90.9% | [4] |
| DTP vs none, mortality (not significant) | 1.51 (0.96-2.38) | [5] |
What the retrieval does not contain: any large trial of the full infant schedule versus no vaccines, tracking all-cause mortality or chronic disease over years. Maternal influenza and pertussis vaccination showed lower all-cause infant mortality in one large Australian cohort [1], but that is a different question. The safety data you would want for a decision about your own child largely does not exist in these records.
My call: for measles, rotavirus, and pneumococcal disease in high-risk settings, the hard-outcome benefit is real and the disease can kill an infant. For the rest, the burden has not been met, and you are entitled to ask for the vaccinated-versus-unvaccinated data before consenting. Confidence: moderate on the disease-specific benefits, low on the long-term safety picture.
Sources used 7
-
Neonatal and infant mortality after maternal influenza and pertussis vaccination: Probabilistically linked cohort study
A large population-based cohort in three Australian jurisdictions linked maternal vaccination data with infant outcomes to evaluate whether in-pregnancy influenza and/or pertussis vaccination affects neonatal and infant mortality, finding reduced all-cause infant mortality with …
DOI: 10.1080/21645515.2025.2587307 -
Impact of childhood vaccination on reducing mortality from vaccine‑preventable diseases: an epidemiological study
A retrospective secondary-data review reports that routine childhood rotavirus, pneumococcal, and measles vaccination reduced child hospitalizations and mortality, citing prior modeling and observational studies, while noting measles resurgence from coverage declines.
DOI: 10.70164/ihsr.v1i3.36 -
Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States
Infant PCV7 vaccination was associated with substantial reductions in pneumococcal pneumonia hospitalizations and in-hospital mortality across all U.S. age groups from 2000 to 2006; model estimates indicate most of the prevented pneumonia burden occurred in adults through herd i…
DOI: 10.1128/mbio.00309-10 -
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
ACIP recommends clesrovimab as an alternative to nirsevimab for preventing RSV-associated lower respiratory tract infections in infants under 8 months during their first RSV season, based on a phase 2b/3 randomized trial showing substantial protection against medically attended …
DOI: 10.15585/mmwr.mm7432a3 -
Diphtheria-tetanus-pertussis vaccine mortality
This narrative review found no consistent evidence that DTP vaccination increases child mortality; large observational and randomized data showed mostly null or lower mortality, but residual confounding limits observational studies.
DOI: 10.61409/v07240483 -
Signatures of neurological adverse events after vaccination
A retrospective VAERS analysis of age-stratified neurological adverse events reported after vaccination identified high associations of aphasia, autism spectrum disorder, and speech disorder with MMR and hepatitis B vaccines in infants up to 3 years, febrile convulsion and synco…
DOI: 10.36922/an.2258 -
Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania
During Romania's 2016-2019 measles outbreak, 17,533 cases and 64 deaths occurred, mostly in unvaccinated individuals, with genotype B3 predominant (n=269) and D8 sporadic (n=9), indicating multiple virus importations and insufficient MMR coverage.
DOI: 10.2807/1560-7917.es.2019.24.29.1900041